Summary by Futu AI
Michael R. McMullen, a director and 10% owner of Bristol-Myers Squibb, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on July 1, 2024. The Form 3 submission, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that McMullen does not beneficially own any non-derivative or derivative securities of the company. The filing, signed by attorney-in-fact Lisa A. Atkins on behalf of McMullen, was completed on July 2, 2024. This formality is part of the regulatory requirements for individuals in McMullen's position, providing transparency about the holdings of company insiders.